

Our mission is to expedite discoveries and innovations across Texas to reduce the burden of cancer.




THE IMMUNOTHERAPY FRONTIER



Dr. Jim Allison, MD Anderson Cancer Center

Between 1982 and 1996, Dr.
Jim Allison and his colleagues
hunted for, and succeeded in
discovering, a protein in the
human body, CTLA-4.
They proved it behaves
like a brake on the immune
system, contrary to the
view most researchers held
at the time. The discovery
led to the development
of the drug Yervoy.



Today, Dr. Allison leads the Immunology Department at MD Anderson Cancer Center and has a combination of talented research associates and laboratory infrastructure working together to translate cancer immunotherapies to the bedside. Dr. Allison is the recipient of the 2018 Nobel Prize in Physiology or Medicine along with Tasuku Honjo.



Karlee Steele, Cancer Survivor

In 2011 Karlee Steele was diagnosed with stage 1 melanoma on her skin. It was treated through a simple procedure.

In 2015, Karlee faced a second melanoma diagnosis that had spread to the lymph node under her right arm. At MD Anderson, Karlee learned the cancer had developed into a stage 3B melanoma tumor.



Karlee was treated by the immunotherapy pioneered by Dr. Allison and today, is cancer free. "As I learned more about immunotherapy and the advancements of Dr. Allison and what he has done, I was blessed to hear that he was obviously back in Texas doing the work that all cancer patients need"

— Karlee Steele
Cancer Survivor

INNOVATION IN THE STATE'S CAPITAL

The University of Texas at Austin could be the epicenter for a game-changing cancer-detection technology—the MasSpec Pen—a device that can rapidly identify breast, thyroid, lung, ovarian and brain cancers with more than 96 percent accuracy.

A team of scientists led by Dr. Livia Schiavinato Eberlin is using CPRIT grants totaling \$2.2 million to date to push the development of the MasSpec pen forward. The pen enables a controlled and automated delivery of a discrete water droplet to a tissue surface for efficient extraction of biomolecules, which are then delivered to a mass spectrometer for molecular analysis.

In 2016, Dr. Eberlin came to Austin to be an assistant professor in the chemistry department at the University of Texas and is a 2018 MacArthur Foundation "Genius" Awardee.









PRODUCT DEVELOPMENT RESEARCH PROGRAM

43

Product Development Research Grants 23

Product Development Research Grantees Established Connections to Texas Academic Institutions \$437,072,786

Amount of
Product Development
Research Grants

17

Companies Conducting Clinical Trials \$3.08 B

Follow-On Funding



ACADEMIC RESEARCH PROGRAM

1.178

Academic Research Grants \$1,718,225,104

Amount of Academic Research Grants

181

CPRIT Scholars
Recruited to Texas

\$542,073,604

Amount of Recruitment Grants

BUILDING BRIDGES BETWEEN THE PRIVATE SECTOR & ACADEMIC INSTITUTIONS



Harpreet Singh, President and CEO,



2015

German immunotherapy company Immatics
Biotechnologies, one of 34
CPRIT Product Development grant recipients, opened a US office in Houston after receiving a grant from CPRIT for \$19.7 million. Immatics has matched the award with \$40 million in private equity follow-on funding.

2017

Immatics US Inc. President and CEO Harpreet Singh struck up a strategic partnership with MD Anderson Cancer Center's Division Head of Cancer Medicine Patrick Hwu, who is a recipient of over \$4 million in CPRIT Academic Research grants, and CPRIT Scholar Cassian Yee, Director of Solid Tumor Cell Therapy, who was recruited to Texas from the Fred Hutchison Cancer Research Center in Seattle, Washington. Through this collaboration, Immatics US initiated cutting-edge immunotherapy clinical trials in 2017, working to further develop and potentially commercialize immunotherapy research at MD Anderson.

TODAY

The company has established a state-of-the-art research and development and GMP manufacturing facility at the Life Science Plaza in Houston that currently employs 50 full-time staff. This collaboration contributed to a new partnership with biopharmaceutical giant Amgen, yielding \$30 million in additional funding.



CREATING ACCESS TO BREAST AND CERVICAL CANCER SCREENINGS IN WEST TEXAS

The Texas Panhandle is largely comprised of rural, medically underserved communities facing socio-economic and geographical barriers that limit access to health care. In 2010, more women on a percentile basis died from breast cancer in the Texas Panhandle than the rest of the state. The 26-county region also has the highest cervical cancer mortality rate in the state.

CPRIT awarded a prevention grant to Dr. Rakhshanda Rahman of the Amarillo Breast Center of Excellence at Texas Tech University Health Sciences Center to deliver breast and cervical cancer services in the Texas Panhandle.

The program—Access to Breast and Cervical Care for West Texas—has increased the number of screening mammograms year-over-year by 26 percent since 2009, reducing the percentage of late stage breast cancers from 21.2% to 4.5% in the 26-county region. The annual number of Pap tests increased by 21% since 2013, with the number of HPV vaccinations increasing by an incredible 94%. These efforts are significantly reducing the emotional and economic burden of cancer in the Texas Panhandle.



"I was told about the breast cancer screening funded by the CPRIT project, available for women just like me with no job and no insurance. I was so thankful my cancer was spotted early.

PREVENTION PROGRAM

226

\$249,967,148


Amount of **Prevention Grants** 2,951,714

Services Provided

2,773,021

Clinical Services Provided. Includes 1,325,884 screening and diagnostics, with **17,312** cancer precursors and **3,677** cancers detected

Projects: 41



Delivered 5.7 million prevention services to Texans from all 254 counties

